Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity

k-Means found stable, slow, and rapid cognitive decline clusters in amyloid beta-positive (Aβ+) cases. Higher baseline plasma phosphorylated tau-217 (p-tau217) levels predicted faster cognitive decline. Longitudinal increases in plasma p-tau217 were steepest in rapid decliners. Plasma p-tau217 tracks clinical progression heterogeneity in Aβ+ cases. Cognitive stage and amyloid alone may miss severity and risk in early-stage Alzheimer's disease.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-05-01
DOI
https://doi.org/10.1002/alz.70319
Citations
9
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
13.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity

Lene Pålhaugen, Ragnhild Eide Skogseth, Argonde C. van Harten, Michael Turton et al.
9 citations
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
13.24
article

Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity

Lene Pålhaugen, Ragnhild Eide Skogseth, Argonde C. van Harten, Michael Turton, Berglind Gísladóttir, Kaj Blennow, Bjørn‐Eivind Kirsebom, Fernando González‐Ortiz, Knut Waterloo, Tormod Fladby, Geir Bråthen, Jonas Alexander Jarholm, Arvid Rongve, Sinthujah Vigneswaran, Per Selnes, Henrik Zetterberg, Peter Harrison, Betty Tjims
article en
9 citations

Abstract

k-Means found stable, slow, and rapid cognitive decline clusters in amyloid beta-positive (Aβ+) cases. Higher baseline plasma phosphorylated tau-217 (p-tau217) levels predicted faster cognitive decline. Longitudinal increases in plasma p-tau217 were steepest in rapid decliners. Plasma p-tau217 tracks clinical progression heterogeneity in Aβ+ cases. Cognitive stage and amyloid alone may miss severity and risk in early-stage Alzheimer's disease.

Alzheimer s & DementiaVol. 21(5)
University of Science and Technology of China (CN), University Hospital of North Norway (NO), University of Oslo (NO), Norwegian University of Science and Technology (NO), Akershus University Hospital (NO), Sahlgrenska University Hospital (SE), Privatsykehuset Haugesund (NO), Sorbonne Université (FR), St Olav's University Hospital (NO), Amsterdam Neuroscience (NL), Pitié-Salpêtrière Hospital (FR), UK Dementia Research Institute (GB), Haraldsplass Diakonale Sykehus (NO), National Hospital for Neurology and Neurosurgery (GB), Amsterdam University Medical Centers (NL), Institut du Cerveau (FR), University of Bergen (NO), University College London (GB), UiT The Arctic University of Norway (NO), Vrije Universiteit Amsterdam (NL), University of Gothenburg (SE), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Alzheimer's Association, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, European Partnership on Metrology, European Commission, Hjärnfonden, Vetenskapsrådet, Norges Forskningsråd, UK Dementia Research Institute, Fondation pour la Recherche sur Alzheimer, HORIZON EUROPE Framework Programme
Good health and well-being
Openalex Percentile: Top 1%
Dementia and Cognitive Impairment Research
13.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.